1. Home
  2. DAWN vs PRLB Comparison

DAWN vs PRLB Comparison

Compare DAWN & PRLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAWN
  • PRLB
  • Stock Information
  • Founded
  • DAWN 2018
  • PRLB 1999
  • Country
  • DAWN United States
  • PRLB United States
  • Employees
  • DAWN N/A
  • PRLB 2415
  • Industry
  • DAWN Biotechnology: Pharmaceutical Preparations
  • PRLB Metal Fabrications
  • Sector
  • DAWN Health Care
  • PRLB Industrials
  • Exchange
  • DAWN Nasdaq
  • PRLB Nasdaq
  • Market Cap
  • DAWN 1.2B
  • PRLB 1.0B
  • IPO Year
  • DAWN 2021
  • PRLB 2012
  • Fundamental
  • Price
  • DAWN $12.43
  • PRLB $40.57
  • Analyst Decision
  • DAWN Strong Buy
  • PRLB Buy
  • Analyst Count
  • DAWN 7
  • PRLB 4
  • Target Price
  • DAWN $36.17
  • PRLB $40.33
  • AVG Volume (30 Days)
  • DAWN 782.5K
  • PRLB 273.4K
  • Earning Date
  • DAWN 02-25-2025
  • PRLB 02-07-2025
  • Dividend Yield
  • DAWN N/A
  • PRLB N/A
  • EPS Growth
  • DAWN N/A
  • PRLB 0.37
  • EPS
  • DAWN N/A
  • PRLB 0.66
  • Revenue
  • DAWN $101,953,000.00
  • PRLB $500,890,000.00
  • Revenue This Year
  • DAWN N/A
  • PRLB $3.49
  • Revenue Next Year
  • DAWN $35.37
  • PRLB $4.82
  • P/E Ratio
  • DAWN N/A
  • PRLB $61.45
  • Revenue Growth
  • DAWN N/A
  • PRLB N/A
  • 52 Week Low
  • DAWN $11.13
  • PRLB $25.76
  • 52 Week High
  • DAWN $18.07
  • PRLB $46.73
  • Technical
  • Relative Strength Index (RSI)
  • DAWN 52.15
  • PRLB 44.05
  • Support Level
  • DAWN $11.65
  • PRLB $41.37
  • Resistance Level
  • DAWN $12.54
  • PRLB $45.48
  • Average True Range (ATR)
  • DAWN 0.47
  • PRLB 1.86
  • MACD
  • DAWN 0.02
  • PRLB -0.27
  • Stochastic Oscillator
  • DAWN 80.53
  • PRLB 12.38

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

About PRLB Proto Labs Inc. Common stock

Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. The majority of its revenue is derived from the United States of America.

Share on Social Networks: